Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Geospatial analyses are increasingly used in population oncology. We provide a first review of geospatial analysis in Canadian population oncology research, compare to international peers, and identify future directions. Geospatial-focused peer-reviewed publications from 1992-2020 were compiled using PubMed, MEDLINE, Web of Science, and Google Scholar. Abstracts were screened for data derived from a Canadian cancer registry and use of geographic information systems. Studies were classified by geospatial methodology, geospatial unit, location, cancer site, and study year. Common limitations were documented from article discussion sections. Our search identified 71 publications using data from all provincial and national cancer registries. Thirty-nine percent ( = 28) were published in the most recent 5-year period (2016-2020). Geospatial methodologies included exposure assessment (32.4%), identifying spatial associations (21.1%), proximity analysis (16.9%), cluster detection (15.5%), and descriptive mapping (14.1%). Common limitations included confounding, ecologic fallacy, not accounting for residential mobility, and small case/population sizes. Geospatial analyses are increasingly used in Canadian population oncology; however, efforts are concentrated among a few provinces and common cancer sites, and data are over a decade old. Limitations were similar to those documented internationally, and more work is needed to address them. Organized efforts are needed to identify common challenges, develop leading practices, and identify shared priorities.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-20-0092DOI Listing

Publication Analysis

Top Keywords

population oncology
16
canadian population
12
geospatial analyses
8
analyses increasingly
8
common limitations
8
limitations documented
8
geospatial
7
current state
4
state geospatial
4
geospatial methodologic
4

Similar Publications

Background: Polygenic risk scores (PRS) are not yet standard in clinical risk assessments for familial breast cancer in Sweden. This study evaluated the distribution and impact of an established PRS (PRS) in women undergoing clinical sequencing for hereditary breast cancer.

Findings: We integrated PRS into a hereditary breast cancer gene panel used in clinical practice and calculated scores for 262 women.

View Article and Find Full Text PDF

Background: The Comprehensive Cancer Center Munich has established a central contact point for cancer patients and their caregivers, which is associated with a multidisciplinary supportive care center. The platform facilitates multifaceted enquiries about access to supportive care, second opinions and specialist care. The aim of this study was to investigate the utilization of the contact platform during a period of 31 months.

View Article and Find Full Text PDF

Unlabelled: The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. This guideline is relevant for all healthcare professionals involved in osteoporosis management.

Introduction: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013, 2017 and 2021.

View Article and Find Full Text PDF

To address the challenges of self-care in oncology, gamification emerges as an innovative strategy to enhance health literacy and self-care among individuals with oncological disease. This study aims to explore and map how gamification can promote health literacy for self-care of oncological diseases. A scoping review was conducted following the Joanna Briggs Institute guidelines and the PRISMA-ScR Checklist developed for scoping reviews.

View Article and Find Full Text PDF

Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care.

View Article and Find Full Text PDF